Project Experience
Project Case
FAQ
Client X required 96 monoclonal antibodies (mAbs) and 49 bispecific antibodies (BsAbs) for experimental validation.
1）Quantity：≥2 mg per sample
2）Delivery standards：mAb SDS-PAGE>95%，SEC>90%；BsAb SDS-PAGE>90%，SEC>80%, Endotoxin＜1 EU/mg
3）Lead time：3-week turnaround, including delivery
Bulk fragment synthesis
High-throughput construction of proprietary vectors
ExpiCHO high-throughput electroporation expression (20 mL)
Magnetic bead-based affinity chromatography
High-throughput physicochemical analysis
Cold-chain transportation
The monoclonal antibodies (mAbs) demonstrated an average expression level of 400 μg/mL, with a peak expression level reaching 809 μg/mL, and all mAbs yielded over 6 mg of purified antibody post-affinity purification.
The bispecific antibodies (BsAbs) achieved an average expression level of 420 μg/mL, with all BsAbs exceeding 200 μg/mL in expression, and every BsAb preparation consistently generated over 4.5 mg of purified antibody following affinity purification.
Following single-step affinity chromatography, over 98% of mAb exhibited SEC purity exceeding 95%, while BsAbs demonstrated SEC purity above 90% in over 80% of cases, with the remaining batches maintaining purity above 80% — all requiring only one additional polishing step to meet release specifications.
Customized codon optimization strategies enhance antibody expression efficiency.
Integrated high-throughput automated platforms ensure seamless workflow coordination, enabling 14-day rapid antibody delivery.
Proven preparation expertise with adaptable solutions guarantees first-time project success, eliminating rework risks.
Client X required 96 monoclonal antibodies (mAbs) and 49 bispecific antibodies (BsAbs) for experimental validation.
1）Quantity：≥2 mg per sample
2）Delivery standards：mAb SDS-PAGE>95%，SEC>90%；BsAb SDS-PAGE>90%，SEC>80%, Endotoxin＜1 EU/mg
3）Lead time：3-week turnaround, including delivery
Bulk fragment synthesis
High-throughput construction of proprietary vectors
ExpiCHO high-throughput electroporation expression (20 mL)
Magnetic bead-based affinity chromatography
High-throughput physicochemical analysis
Cold-chain transportation
The monoclonal antibodies (mAbs) demonstrated an average expression level of 400 μg/mL, with a peak expression level reaching 809 μg/mL, and all mAbs yielded over 6 mg of purified antibody post-affinity purification.
The bispecific antibodies (BsAbs) achieved an average expression level of 420 μg/mL, with all BsAbs exceeding 200 μg/mL in expression, and every BsAb preparation consistently generated over 4.5 mg of purified antibody following affinity purification.
Following single-step affinity chromatography, over 98% of mAb exhibited SEC purity exceeding 95%, while BsAbs demonstrated SEC purity above 90% in over 80% of cases, with the remaining batches maintaining purity above 80% — all requiring only one additional polishing step to meet release specifications.
Project Experience
Project Case
FAQ
Client X required 96 monoclonal antibodies (mAbs) and 49 bispecific antibodies (BsAbs) for experimental validation.
1）Quantity：≥2 mg per sample
2）Delivery standards：mAb SDS-PAGE>95%，SEC>90%；BsAb SDS-PAGE>90%，SEC>80%, Endotoxin＜1 EU/mg
3）Lead time：3-week turnaround, including delivery
Bulk fragment synthesis
High-throughput construction of proprietary vectors
ExpiCHO high-throughput electroporation expression (20 mL)
Magnetic bead-based affinity chromatography
High-throughput physicochemical analysis
Cold-chain transportation
The monoclonal antibodies (mAbs) demonstrated an average expression level of 400 μg/mL, with a peak expression level reaching 809 μg/mL, and all mAbs yielded over 6 mg of purified antibody post-affinity purification.
The bispecific antibodies (BsAbs) achieved an average expression level of 420 μg/mL, with all BsAbs exceeding 200 μg/mL in expression, and every BsAb preparation consistently generated over 4.5 mg of purified antibody following affinity purification.
Following single-step affinity chromatography, over 98% of mAb exhibited SEC purity exceeding 95%, while BsAbs demonstrated SEC purity above 90% in over 80% of cases, with the remaining batches maintaining purity above 80% — all requiring only one additional polishing step to meet release specifications.
Customized codon optimization strategies enhance antibody expression efficiency.
Integrated high-throughput automated platforms ensure seamless workflow coordination, enabling 14-day rapid antibody delivery.
Proven preparation expertise with adaptable solutions guarantees first-time project success, eliminating rework risks.
Client X required 96 monoclonal antibodies (mAbs) and 49 bispecific antibodies (BsAbs) for experimental validation.
1）Quantity：≥2 mg per sample
2）Delivery standards：mAb SDS-PAGE>95%，SEC>90%；BsAb SDS-PAGE>90%，SEC>80%, Endotoxin＜1 EU/mg
3）Lead time：3-week turnaround, including delivery
Bulk fragment synthesis
High-throughput construction of proprietary vectors
ExpiCHO high-throughput electroporation expression (20 mL)
Magnetic bead-based affinity chromatography
High-throughput physicochemical analysis
Cold-chain transportation
The monoclonal antibodies (mAbs) demonstrated an average expression level of 400 μg/mL, with a peak expression level reaching 809 μg/mL, and all mAbs yielded over 6 mg of purified antibody post-affinity purification.
The bispecific antibodies (BsAbs) achieved an average expression level of 420 μg/mL, with all BsAbs exceeding 200 μg/mL in expression, and every BsAb preparation consistently generated over 4.5 mg of purified antibody following affinity purification.
Following single-step affinity chromatography, over 98% of mAb exhibited SEC purity exceeding 95%, while BsAbs demonstrated SEC purity above 90% in over 80% of cases, with the remaining batches maintaining purity above 80% — all requiring only one additional polishing step to meet release specifications.
+86 21 3368 1627
protein@sanyoubio.com
abx.sanyoubio.com.cn
